EZH2 and neoplasm: GD2-specific CAR T cells reduced the tumour burden in vitro and in vivo in xenograft models of GD2-expressing lung tumours (SCLC and NSCLC), and the susceptibility of tumours to this treatment was enhanced by pre-treatment with tazemetostat (EZH2 inhibitor), which can upregulate GD2 expression in tumour cells [167].